Study Design. Economic evaluation from the societal perspective, using data from various sources, including a multicenter, randomized clinical trial. Objective. To evaluate the relative cost-effectiveness of interspinous process decompression using the X-STOP ® Interspinous Spacer (Medtronic, Inc, Sunnyvale, CA) compared with both conservative care (CC) and laminectomy (LAMI) for patients moderately impaired by lumbar spinal stenosis. Summary of Background Data. Placement of the X-STOP spacer is a minimally invasive surgical treatment for patients experiencing symptoms of lumbar spinal stenosis. The cost-effectiveness of the X-STOP spacer in the United States has not been evaluated. Methods. A cost-effectiveness analysis was conducted using clinical, quality-of-life, and economic data from a total of 131 moderately impaired lumbar spinal stenosis patients (aged 50 years or older) randomly assigned to the X-STOP device (n ϭ 69) or CC (n ϭ 62) and followed up for 2 years. Data for LAMI are from patients who failed CC during the clinical trial and underwent LAMI, Medicare claims data, and published literature. An economic model comparing the X-STOP spacer with CC and LAMI was developed, and the incremental cost-effectiveness ratios were calculated in 2009 US dollars and reported. The primary clinical outcome measure was determined using the Zurich Claudication Questionnaire. The 36-Item Short-Form was used to calculate quality-adjusted life-years. Costs included fi rst-and second-line treatment costs, follow-up costs, and adverse event-related treatment costs. Results. For patients treated with the X-STOP spacer in the outpatient setting, the X-STOP spacer was cost-effective when compared with CC (the incremental cost-effectiveness ratio relative to CC was $17,894 per quality-adjusted life-year) and the X-STOP spacer was dominant when compared with LAMI (i.e., the X-STOP spacer both was less expensive and provided better quality of life than LAMI). Conclusion. In lumbar spi nal stenosis patients with moderately impaired physical functioning, the clinical and quality-of-life benefi ts of the X-STOP spacer yielded favorable cost-effectiveness ratios. Placement of the X-STOP spacer performed in the outpatient setting compared with LAMI was more cost-effective than treatments such as hip replacement surgery ($2004 per quality-adjusted lifeyear). These results support the use of interspinous process devices to treat patients experiencing symptoms of lumbar spinal stenosis.
L umbar spinal stenosis is defi ned as a narrowing of the spinal canal and peripheral neural pathways, resulting in compression of neural elements. Treatment initially consists of conservative care (CC), with nonsteroidal antiinfl ammatory medication, oral steroids, analgesics, epidural steroid injections, physical therapy, and spinal manipulation. Spinal decompression with laminectomy (LAMI), with or without fusion, is the standard surgical procedure for patients failing CC. Surgical success rates vary widely in the clinical literature because of variations in the defi nition of treatment success, patient sample, and clinical endpoint measures. In addition, LAMI complication and reoperation rates are substantial, with intraoperative complication rates ranging from 9% to 12%, [1] [2] [3] postoperative complication rates ranging from 12% to 29% 1-2,4-6 depending on age and comorbidity status, 7 and reoperation rates ranging from 6% at 2-year follow-up to 23% at 7-to 10-year follow-up. 1, [7] [8] [9] [10] Interspinous process decompression has been developed as a minimally invasive surgical treatment for patients experiencing symptoms of lumbar spinal stenosis. The clinical effectiveness criteria for the X-STOP spacer trial included, but were not limited to, those patients who had undergone prior lumbar spinal surgery, had more than two affected levels, had cauda equine syndrome, had other defi ned neurologic defi cits or signifi cant instability of the spine, had signifi cant scoliosis of the spine (Cobb angle greater than 25Њ), had spondylolisthesis greater than grade 1 at affected levels, and had severe osteoporosis. The clinical trial demonstrated that patients who received the X-STOP spacer had signifi cantly better outcomes in each domain of the ZCQ (specifi cally, physical function, symptom severity, and patient satisfaction) relative to CC patients. 11 Clinical, adverse-event, and quality-of-life data from the X-STOP spacer clinical trial were made available for this cost-effectiveness analysis.
Of note, the present cost-effectiveness analysis incorporates only those data from the X-STOP spacer-clinical trial patients diagnosed with moderate-to-severe lumbar spinal stenosis (N ϭ 131; X-STOP: n ϭ 69, CC: n ϭ 62). 15 Among these patients, the mean age was 69.8 years (70.2% were 65 years or older), 72.3% had one affected level, 27.7% had two affected levels, and the mean baseline ZCQ physical function score was 2.68. Treatment success, defi ned for this cost-effectiveness study as meeting all the three ZCQ criteria, 11, 15 was significantly higher in patients receiving the X-STOP spacer than in those undergoing CC (55.1% vs. 4.8%, P Ͻ 0.001) 15 ; the incidence of X-STOP device-related adverse events (i.e., device migration, dislodgement, or removal) was 2.9%. 15 Comparison of the X-STOP spacer with LAMI was not an objective of the randomized trial comparing the X-STOP spacer with CC. Data for LAMI come from multiple sources, including health insurance claims data and the published literature. Specifi cally, data on the clinical effectiveness of LAMI come from the published literature. Adverse event rates for LAMI come from MedPAR and MedStat Market Scan claims databases, while associated LAMI adverse event-related costs come from MedPAR. Utility values for LAMI treatment-related adverse events come from the clinical panel using the X-STOP spacer clinical trial data as reference points. First-and secondline LAMI treatment costs come from MedPAR. LAMI followup costs come from a number of sources, including MedPAR, RedBook, Medicare Outpatient Prospective Payment System, and Medicare Physician Fee Schedule. LAMI quality-adjusted life-years (QALYs) com e from SF-36 data for CC patients who proceeded to LAMI during the X-STOP spacer clinical trial.
Analysis Method
Cost-utility analysis is a type of cost-effectiveness analysis in which outcomes are adjusted for quality of life, often using QALYs gained. The quality adjustment comes from utilities, numbers that refl ect an individual's preference for particular health outcomes. 16 In this study, we developed an incremental cost-effectiveness analysis to evaluate the 2-year clinical, economic, and quality-of-life outcomes associated with the three lumbar spinal stenosis treatment strategies: CC, the X-STOP device, and LAMI. A multispecialty clinical panel of fi ve physicians (two neurosurgeons, one orthopedic surgeon, and two physiatrists) provided the clinical framework for the economic (treatment success rate) of the X-STOP ® Interspinous Spacer (Medtronic, Inc, Sunnyvale, CA) has been demonstrated in a prospective, randomized clinical trial to be superior to continued CC. 11 In addition, the X-STOP device has demonstrated superior effi cacy compared with CC in improving the quality of life (as measured by the 36-Item Short Form Health Survey ) in patients with lumbar spinal stenosis. 12 After at least 6 months of CC, this procedure can be a logical next step for the treatment of lumbar spinal stenosis symptoms. However, the economic aspects of the X-STOP spacer in the United States have not been explored.
This study evaluates the cost-effectiveness of the X-STOP spacer relative to continued CC or LAMI in lumbar spinal stenosis patients with moderately impaired physical functioning, using the analysis methodology termed "societal perspective" analysis. 13 Cost-effectiveness analysis compares two or more alternative health interventions in terms of their costs and benefi ts (or improvement in patient quality-of-life) to evaluate whether the added benefi ts outweigh the incremental costs.
14 Our analyses are primarily based on data collected during a multicenter, prospective, randomized clinical trial of the X-STOP spacer, supplemented with published data on LAMI. The X-STOP spacer is designed to create and maintain distraction of the spinous processes at the treatment level, while enabling lumbar extension at other levels. The X-STOP interspinous spacer is approved by the US Food and Drug Administration for treating patients aged 50 years or older with symptoms of neurogenic intermittent claudication and a confi rmed diagnosis of lumbar spinal stenosis in patients who experience moderate physical impairment with relief in fl exion. The X-STOP spacer is indicated for patients who have undergone at least 6 months of CC and may be implanted at one or two lumbar levels when treatment is indicated at no more than two levels.
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MATERIALS AND METHODS
This study incorporates clinical, quality-of-life, and economic data collected during a randomized trial comparing the X-STOP device with CC. Conducted between May 2000 and July 2003, the trial involved nine US sites and included 191 patients with mild to severe lumbar spinal stenosis.
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During the clinical trial, CC was defi ned as at least one epidural steroid injection, supplemented by nonsteroidal anti-infl ammatory medication, oral steroids, analgesics, physical therapy, and spinal manipulation therapies, as appropriate. 11 Patients were eligible to participate in the clinical trial if they were at least 50 years of age, had neurogenic intermittent claudication, secondary to imaging-confi rmed lumbar spinal stenosis at 1 or 2 levels, had pain relief in fl exion, were able to sit 50 minutes without pain, were able to walk 50 ft or more, and had undergone at least 6 months of CC. Of note, the present cost-effectiveness analysis incorporates only those data from X-STOP spacer clinical trial patients in the indicated population (N ϭ 131; X-STOP: n ϭ 69, CC: n ϭ 62), that is, moderately impaired lumbar spinal stenosis patients who scored greater than 2 in the physical function domain of the Zurich Claudication Questionnaire (ZCQ).
15 Key e xclusion model and made fi nal decisions on parameters. This research was performed according to guidelines established to minimize confl ict of interest in pharmacoeconomic studies. 17, 18 The authors independently framed the cost-effectiveness analysis, including the perspective to adopt, settings of care to evaluate, costs to measure, outcomes to assess, and assumptions to make. The sponsor was invited to review the draft manuscript for accuracy of describing the X-STOP interspinous spacer, clinical trial data, and device cost. All fi nal editorial decisions were made by the coauthors.
The incremental cost-effectiveness ratio is calculated as the difference in costs incurred divided by the difference in QALYs accrued between the two treatments being compared. The term dominant is used to refl ect instances in which one intervention is both less expensive and more effective (i.e., offers better quality of life) than the alternative intervention. The present societal perspective-type analysis considers all relevant costs and benefi ts, regardless of where incurred or accrued (patient, physician, or payer). Direct medical costs include fi rst-and second-line treatments, follow-up, and adverse events. All results are expressed in 2009 US dollars. Sensitivity analyses assessed the external validity and generalizibility of our estimates. 19 A 2-year time horizon was selected because the published follow-up data on the X-STOP device were limited to 2 years. Sensitivity analysis was performed to address this limitation. Costs and health effects are not discounted, given the 2-year time frame. Parameter estimates derived from the X-STOP spacer clinical trial, a comprehensive literature review, Medicare claims data, and the opinions of the clinical panel are provided in Table 1 .
Assumptions
Several assumptions were made to construct this costeffectiveness model: (1) This analysis applies only to modera tely impaired lumbar spinal stenosis patients, aged 50 years or older with one or two affected levels, who have failed at least 6 months of CC and are candidates for the X-STOP spacer, continued CC, or LAMI; (2) in the base case analysis, we assumed that the X-STOP procedure is performed in the outpatient setting; (3) only those patients who are classifi ed as clinical failures undergo additional treatment, as depicted in Table 1 ; (4) the sequelae of treatment-related adverse events are treated the same, irrespective of the fi rst-line treatment; (5) treatment success and reoperation rates among patients undergoing LAMI without fusion versus those undergoing LAMI with fusion are similar 8, 20 ; (6) LAMI patients undergoing reoperation after fi rst-line treatment failure have an increased probability of undergoing LAMI with fusion; (7) the quality-of-life effect of LAMI does not change after 1-year postoperation; (8) this analysis does not apply to workman's compensation patients because we excluded fi ve patients who were receiving workman's compensation (three X-STOP spacer, two CC).
Utility Values
This cost-utility analysis is based on the idea that diminishing health results in diminished quality of life. This is accomplished by applying different utility weights to life expectancy according to the level of health experienced over time. Utility weights refl ect the preference for a particular health outcome and range from 0 ("death") to 1 ("full health"). QALYs were calculated from the utility values by estimating the area under the curve mapped out by the utility values over time. Utility values were derived from three sources: (1) for X-STOP spacer and CC, SF-36 data (Medical Outcomes Study 36-item Short Form Health Survey) from the X-STOP spacer clinical trial at baseline, 6 weeks, 6 months, 1 year, and 2 years; (2) for LAMI, SF-36 data at baseline and 1 year from CC patients who proceeded to LAMI during the X-STOP spacer clinical trial (n ϭ 21); and (3) for treatment-related adverse events, estimates from the clinical panel using the trial data as reference points. Because the SF-36 assessment asks about the previous 4 weeks, the 6-week SF-36 assessment in the X-STOP spacer clinical trial did not address the time from baseline through week 2. Therefore, disutilities associated with treatment-related adverse events were assumed to occur at time zero and were applied for a 2-week duration to the percentage of each adverse event that occurred intraoperatively or within 2 weeks after surgery (Table 2) .
SF-36 scores for the X-STOP device, CC, and LAMI were transformed to utilities on the basis of equations from Nichol et al. 21 Before e liciting utility estimates from the panel for treatment-related adverse events, we transformed the reference utilities (for X-STOP spacer and CC, success and failure; and for deep wound infection, dural tear, chronic back pain [symptoms of spinal stenosis not improved], and degenerative spondylolisthesis and spinal stenosis free of symptoms 22 ) to rating scale values using a power curve transformation 23 and placed the values on a rating scale ranging from 0 ("death") to 1 ("full health"). The panelists ranked the treatment-related adverse events on the rating scale by indicating a patient's likely preference for each event. Panelists' values were transformed back into utilities for use in the cost-effectiveness model (Table 2) .
Medical Resource Utilization and Costs
Costs are assessed from the societal perspective. Indirect costs of lost productivity and intangible costs of pain and suffering related to treatment morbidity are not estimated directly but instead are implicitly incorporated in the utility values. To estimate 2-year direct medical costs, panelists enumerated medical resource utilization associated with the three therapeutic alternatives and their potential sequelae. A physician and a billing administrator experienced in medical reimbursement assigned procedure and diagnosis codes to hospitalizations, physician offi ce visits, radiographic imaging studies, laboratory tests, and professional services. After identifying codes for resource use, we derived cost estimates from 2006 national Medicare reimbursement schedules and infl ated these costs to 2009 US dollars, using the medical care component of the consumer price index. 24 Tables 2 and 3 list adverse event-related and treatment-related costs, respectively.
Medicare payments (national averages) were used as a proxy for cost, a well-established methodologic approach for such economic analyses. 25 Professional services associated with hospitalizations and outpatient visits were assigned current procedural terminology codes. 
Sensitivity Analyses
Sensitivity analyses were performed to determine the consequences of making alternative assumptions, for instance, about the defi nition of treatment success, the durability of the X-STOP spacer treatment success rate, the X-STOP device placement setting of care, the number of affected levels, patient age (elderly vs. nonelderly), and the number of QALYs. The generalizibility of the results was assessed using one-way sensitivity analyses and several other analyses, in which multiple parameters were varied simultaneously over plausible ranges. Table 4 reports the 2-year costs, utilities (expressed in QALYs), and cost-effectiveness ratios for moderately impaired lumbar spinal s tenosis patients. 
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RESULTS
Sensitivity Analyses
Sensitivity analysis was used to test the robustness of the results and to determine which variables have a substantial effect on the results. The results generated by the cost-effectiveness model are considered robust because the cost-effectiveness ratios fall within a narrow range when key model assumptions and parameters are varied. In the analyses comparing the X-STOP device with CC, the results were most sensitive to the X-STOP device placement setting of care, the number of QALYs for CC, and the SF-36 transformation algorithm (Table 5 ). In the majority of the sensitivity analyses comparing the X-STOP spacer with LAMI, the X-STOP spacer remained dominant. For example, in lumbar spinal stenosis patients with either one or two affected levels, as well as in nonelderly or elderly patients, X-STOP device placement performed on an outpatient basis both is less expensive and offers improved quality of life ("dominant") relative to LAMI. When X-STOP device placement is performed on an inpatient basis, the cost-effectiveness relative to both CC and LAMI remains favorable.
DISCUSSION
To the best of our knowledge, this study is the fi rst to evaluate the cost-effectiveness of the X-STOP spacer compared to both CC and LAMI in treating lumbar spinal stenosis in the United States. This study demonstrates that the X-STOP spacer is a cost-effective treatment alternative to continued CC and LAMI in moderately impaired lumbar spinal stenosis patients. The favorable cost-effectiveness ratios appear to be due, in part, to the high treatment failure rate in the treatment group that continued to receive CC, the incidence of adverse events associated with LAMI, and the quality-of-life improvements associated with X-STOP spacer treatment. Hsu and colleagues 12 previously reported signifi cant improvements in nearly all SF-36 domains in patients treated with X-STOP relative to CC over 2 years.
Many complications described with LAMI (Table 2 ) prolong hospitalization; most of these are avoided in X-STOP spacer surgery. The low-risk, high-benefi t nature of the X-STOP spacer procedure may suit both older, sicker patients unable to undergo LAMI and younger, active patients who want the better clinical results than what CC offers, but not the higher risk and longer recovery associated with LAMI.
Burnett et al. 28 recently evaluated the cost-effectiveness of X-STOP compared to LAMI by attempting to systematically combine data from numerous studies with different patient populations, methodologies, and outcomes measures. In addition to the caveats discussed in the accompanying Editorial, 29 upon our critical review of this article we identifi ed fi ve limitations that could have substantially infl uenced the results, specifi cally, (1) inclusion of papers from disparate patient populations, (2) use of untransformed SF-36 scores rather than utilities to inform QALYs, (3) inconsistent defi nitions of treatment failure, (4) lack of consideration about the frequency and costs associated with spinal fusion, and (5) outdated X-STOP payment mechanisms and amounts. In light of these limitations, we question the validity of their central fi nding that LAMI is more effective and less costly than the X-STOP spacer.
The National Institute for Health and Clinical Excellence describes £20,000 to £30,000 per QALY (or approximately $40,000-$60,000 per QALY) as its threshold range for cost-effectiveness to inform budget allocation in the United Kingdom. 30 That said, to the best of our knowledge, no defi nitive cost-effectiveness threshold has been defi ned in the United States, although a rule of thumb is that treatments are generally considered cost-effective when their incremental cost-effectiveness ratios are less than $50,000 per QALY. 
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The cost-effectiveness of the X-STOP spacer compares favorably with that of other common orthopedic procedures. X-STOP device placement performed in the outpatient setting compared with CC ($17,894 per QALY) is more cost-effective than cervical discectomy and fusion with autograft versus 30,31 †X-STOP device placement performed in the outpatient setting versus LAMI for treatment of moderately impaired lumbar spinal stenosis patients. The X-STOP spacer is dominant compared with LAMI (i.e., the X-STOP spacer is less expensive and provides better quality of life than LAMI). ‡Total hip replacement surgery versus no total hip replacement surgery in men (60-69 years of age) with arthritis. 33 §X-STOP device placement performed in the outpatient setting versus CC for treatment of moderately impaired lumbar spinal stenosis patients. ||ACDF with autog raph versus ACDF with allograft with plating for treatment of single-level spondylosis. 32 #Lumbar discectomy for patients unresponsive to conservative management versus continued conservative management for herniated intervertebral disc. 34 CC indicates continued conservative care; LAMI, laminectomy; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; ACDF, anterior cervical discectomy and fusion.
with allograft and plating for treatment of single-level anterior cervical spondylosis ($37,856 per QALY). 32 Furthermore, X-STOP device placement performed in the outpatient setting is dominant (less costly and more effective) compared with LAMI and is more cost-effective than total hip replacement surgery in men (60-69 years of age) with arthritis ($2004 per QALY), a procedure widely accepted as cost-effective. 33 As with any cost-effectiveness analysis, the results are only as strong as the underlying assumptions. One assumption warranting further discussion is the defi nition of treatment success. For the cost-effectiveness analysis, treatment success for all the three groups (X-STOP spacer, continued CC, and LAMI) was defi ned as meeting all the three ZCQ criteria (symptom severity, physical function, and patient satisfaction) as defi ned in the X-STOP spacer clinical trial.
11, 15 Tuli et al 35 showed that requiring success in all the three domains of the ZCQ is highly specifi c, but less sensitive, to actual patient preference and physician expectations than if two of the three domains are required for a clinical success. Using the more stringent defi nition of success, the success rates for CC and the X-STOP device were 4.8% and 55.1%, respectively.
11 Based on the ZCQ data collected by Katz et al, 20, 36 47.4% of patients undergoing LAMI met all the three ZCQ criteria. 35 These treatment success rates for the treatment of lumbar spinal stenosis, both operative and nonoperative, are a result of the very stringent defi nition of success. Tuli and colleagues 35 conclude with a recommendation to use two of the three ZCQ domains as the definition of clinical success. When the less stringent defi nition of clinical success for all the groups (X-STOP spacer, continued CC, and LAMI) was used in a sensitivity analysis, the resulting cost-effectiveness ratios remained favorable. In addition, when treatment success is defi ned as meeting all the three ZCQ criteria, as well as no reoperations or device-related complications ("overall treatment success"), the resulting cost-effectiveness ratios remained favorable.
Other study limitations are worth mentioning. In the base case analysis, it was assumed that X-STOP device placement would be performed on an outpatient basis. X-STOP is appropriate for outpatient or 23-hour short stay status because of the ability to perform the procedure using monitored anesthesia care (MAC) anesthesia, the minimal lateral dissection required for insertion, the lack of risk to neural structures, and the short operative time (usually less than 30 minutes for one or two levels). Although X-STOP device placement can be performed on an outpatient basis, patients with certain comorbidities may require that the X-STOP device placement procedure be performed on an inpatient basis. Sensitivity analysis considering X-STOP device placement performed on an inpatient basis continued to yield favorable cost-effectiveness ratios relative to CC and LAMI.
In addition, because the X-STOP spacer clinical trial did not include LAMI as a treatment arm, we reviewed approximately 28 articles seeking LAMI QALYs or LAMI SF-36 scores, by domain, to calculate QALYs for LAMI. However, we were unable to fi nd LAMI QALYs or SF-36 scores, by domain, for a patient population (i.e., lumbar spinal stenosis) similar to that in the X-STOP spacer clinical trial. For instance, the Spine Patient Outcomes Research Trial (SPORT) study and X-STOP spacer clinical trial patient populations differ at baseline for the bodily pain and physical function SF-36 domains (in that, the difference exceeds the respective minimum important difference as cited in the User's Manual for the SF-36 Health Survey for the minimum important differences). 11, 37 In addition, review of the SPORT patient demographic and clinical characteristics (for the randomized group) suggests that the majority of the SPORT patients would not have been eligible for the X-STOP spacer clinical trial. 1, 11 The SPORT study included patients who had not experienced symptoms for at least 6 months, patients with stenosis at level L5-S1, patients with three or more moderate-to-severe stenotic levels, and patients with mild stenosis, 1 whereas the X-STOP spacer clinical trial (and this cost-effectiveness analysis) excluded such patients. 11 To calculate the QALYs for LAMI, we therefore used the SF-36 scores from the patients in the X-STOP spacer clinical trial who failed CC and continued on to LAMI (n ϭ 21). Despite this limitation, the baseline utility for CC, the X-STOP spacer, and LAMI are nearly equivalent at 0.61, 0.62, and 0.59, respectively (Table 1) . Furthermore, because patient preferences for the comprehensive list of treatment-related adverse events for the X-STOP spacer, CC, and LAMI were not available from a single source in the literature, using a utilitybased assessment approach, we elicited utility estimates from the panel. When sensitivity analyses were conducted to address these limitations by increasing the LAMI QALYs, and by excluding treatment-related adverse events and their associated utilities, the X-STOP spacer remained dominant over LAMI. Furthermore, even if we were to assume that the X-STOP spacer and LAMI had equal QALYs, X-STOP device placement performed on an outpatient basis would still provide good value because the X-STOP spacer offers considerable health care cost savings compared with LAMI.
Also, because long-term durability data for the X-STOP spacer are not yet available, it is diffi cult to evaluate the lasting effects of X-STOP spacer treatment on the symptoms of lumbar spinal stenosis. The data from the X-STOP spacer clinical trial show that improvement in symptom severity, physical function, and patient satisfaction was immediate and sustained for the 2 years of follow-up. 11, 12 Currently, 5-year X-STOP spacer data are being collected as part of follow-up to the initial X-STOP spacer clinical trial. To estimate the impact on the cost-effectiveness ratio of the X-STOP spacer durability beyond 2 years, a sensitivity analysis was performed by decreasing the X-STOP spacer treatment success rate by 15%, per the clinical panel. The resulting cost-effectiveness ratios remained favorable relative to both CC and LAMI.
In moderately impaired lumbar spinal stenosis patients treated with the X-STOP spacer, the clinical and quality-of-life benefi ts yielded favorable cost-effectiveness ratios. These results support the use of the X-STOP spacer as a logical and economically viable next step in the treatment of lumbar spinal stenosis after at least 6 months of CC. Patients with prior lumbar surgery or with three or more affected levels were excluded from the X-STOP spacer clinical trial. As such, the safety, effi cacy, and cost-effectiveness of the X-STOP spacer in these subgroups warrant further research.
➢ Key Points
Cost-eff ectiveness analysis provides a construct for comparing diff erent treatments that have various costs, clinical benefi ts, quality-of-life benefi ts, and risks. The cost-eff ectiveness of the X-STOP device compared with conservative care (CC) and laminectomy (LAMI) in patients having lumbar spinal stenosis with moderately impaired physical functioning has not been evaluated in the United States. Placement of the X-STOP spacer in the outpatient setting compared with CC ($17,894 per qualityadjusted life-year [QALY] ) is more cost-eff ective than cervical discectomy with fusion and autograft ($37,856 per QALY). On the basis of a comparison of the X-STOP spacer data from a clinical trial and published data on LAMI, placement of the X-STOP spacer in the outpatient setting both is less expensive and provides better quality of life than that of LAMI and is more cost-eff ective than treatments such as hip replacement surgery ($2004 per QALY), a wellestablished, cost-eff ective procedure. Placement of the X-STOP spacer performed on an outpatient basis both is less expensive and yields greater QALYs than LAMI in patients having lumbar spinal stenosis with one or two aff ected levels, as well as in nonelderly patients (aged 50-64 years) and elderly patients (aged 65 years and older), suggesting that the X-STOP device provides good clinical outcomes and considerable health care cost savings. These results support the use of the X-STOP spacer as the next step in the treatment of lumbar spinal stenosis symptoms after at least 6 months of CC.
